Literature DB >> 26807536

Comparative Responsiveness of the PROMIS Pain Interference Short Forms, Brief Pain Inventory, PEG, and SF-36 Bodily Pain Subscale.

Jacob Kean1, Patrick O Monahan, Kurt Kroenke, Jingwei Wu, Zhangsheng Yu, Tim E Stump, Erin E Krebs.   

Abstract

PURPOSE: To compare the sensitivity to change and the responsiveness to intervention of the PROMIS Pain Interference short forms, Brief Pain Inventory (BPI), 3-item PEG scale, and SF-36 Bodily Pain subscale in a sample of patients with persistent musculoskeletal pain of moderate severity.
METHODS: Standardized response means, standardized effect sizes, and receiver operating curve analyses were used to assess change between baseline and 3-month assessments in 250 participants who participated in a randomized clinical effectiveness trial of collaborative telecare management for moderate to severe and persistent musculoskeletal pain.
RESULTS: The BPI, PEG, and SF-36 Bodily Pain measures were more sensitive to patient-reported global change than the PROMIS Pain Interference short forms, especially for the clinically improved group, for which the change detected by the PROMIS short forms was not statistically significant. The BPI was more responsive to the clinical intervention than the SF-36 Bodily Pain and PROMIS Pain Interference measures. Post hoc analyses exploring these findings did not suggest that differences in content or rating scale structure (number of response options or anchoring language) adequately explained the observed differences in the detection of change.
CONCLUSIONS: In this clinical trial, the BPI and PEG measures were better able to detect change than the SF-36 Bodily Pain and PROMIS Pain Interference measures.

Entities:  

Mesh:

Year:  2016        PMID: 26807536      PMCID: PMC4792763          DOI: 10.1097/MLR.0000000000000497

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  24 in total

Review 1.  Comparative responsiveness of generic and specific quality-of-life instruments.

Authors:  Samuel Wiebe; Gordon Guyatt; Bruce Weaver; Suzan Matijevic; Casey Sidwell
Journal:  J Clin Epidemiol       Date:  2003-01       Impact factor: 6.437

2.  Comparative responsiveness of measures of pain and function after total hip replacement.

Authors:  A K Nilsdotter; E M Roos; J P Westerlund; H P Roos; L S Lohmander
Journal:  Arthritis Rheum       Date:  2001-06

3.  Responsiveness of general health status in chronic low back pain: a comparison of the COOP charts and the SF-36.

Authors:  G Bronfort; L M Bouter
Journal:  Pain       Date:  1999-11       Impact factor: 6.961

4.  Correlation of the National Institutes of Health patient reported outcomes measurement information system scales and standard pain and functional outcomes in spine augmentation.

Authors:  L Shahgholi; K J Yost; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2012-06-14       Impact factor: 3.825

5.  Responsiveness of the WOMAC osteoarthritis index as compared with the SF-36 in patients with osteoarthritis of the legs undergoing a comprehensive rehabilitation intervention.

Authors:  F Angst; A Aeschlimann; W Steiner; G Stucki
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

6.  Stepped Care to Optimize Pain care Effectiveness (SCOPE) trial study design and sample characteristics.

Authors:  Kurt Kroenke; Erin Krebs; Jingwei Wu; Matthew J Bair; Teresa Damush; Neale Chumbler; Tish York; Sharon Weitlauf; Stephanie McCalley; Erica Evans; Jeffrey Barnd; Zhangsheng Yu
Journal:  Contemp Clin Trials       Date:  2012-12-08       Impact factor: 2.226

7.  Chronic musculoskeletal pain and depressive symptoms in the National Health and Nutrition Examination. I. Epidemiologic follow-up study.

Authors:  Guido Magni; Maura Marchetti; Claudio Moreschi; Harold Merskey; Silio Rigatti Luchini
Journal:  Pain       Date:  1993-05       Impact factor: 6.961

8.  The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

Authors:  C A McHorney; J E Ware; A E Raczek
Journal:  Med Care       Date:  1993-03       Impact factor: 2.983

9.  Validation of the Brief Pain Inventory for chronic nonmalignant pain.

Authors:  Gabriel Tan; Mark P Jensen; John I Thornby; Bilal F Shanti
Journal:  J Pain       Date:  2004-03       Impact factor: 5.820

10.  Hip disability and osteoarthritis outcome score (HOOS)--validity and responsiveness in total hip replacement.

Authors:  Anna K Nilsdotter; L Stefan Lohmander; Maria Klässbo; Ewa M Roos
Journal:  BMC Musculoskelet Disord       Date:  2003-05-30       Impact factor: 2.362

View more
  26 in total

1.  Automated Self-management (ASM) vs. ASM-Enhanced Collaborative Care for Chronic Pain and Mood Symptoms: the CAMMPS Randomized Clinical Trial.

Authors:  Kurt Kroenke; Fitsum Baye; Spencer G Lourens; Erica Evans; Sharon Weitlauf; Stephanie McCalley; Brian Porter; Marianne S Matthias; Matthew J Bair
Journal:  J Gen Intern Med       Date:  2019-06-21       Impact factor: 5.128

2.  PROMIS and legacy measures compared in a supportive care intervention for breast cancer patients and caregivers: Experience from a randomized trial.

Authors:  Alla Sikorskii; David Victorson; Patrick O'Connor; Vered Hankin; Abolfazl Safikhani; Tracy Crane; Terry Badger; Gwen Wyatt
Journal:  Psychooncology       Date:  2018-07-17       Impact factor: 3.894

3.  Effect of Mobile Device-Supported Single-Patient Multi-crossover Trials on Treatment of Chronic Musculoskeletal Pain: A Randomized Clinical Trial.

Authors:  Richard L Kravitz; Christopher H Schmid; Maria Marois; Barth Wilsey; Deborah Ward; Ron D Hays; Naihua Duan; Youdan Wang; Scott MacDonald; Anthony Jerant; Joseph L Servadio; David Haddad; Ida Sim
Journal:  JAMA Intern Med       Date:  2018-10-01       Impact factor: 21.873

4.  Pain measurement in research and practice.

Authors:  Kurt Kroenke
Journal:  J Gen Intern Med       Date:  2018-05       Impact factor: 5.128

5.  Use of PROMIS-29® in US Veterans: Diagnostic Concordance and Domain Comparisons with the General Population.

Authors:  Sherri L LaVela; Bella Etingen; Scott Miskevics; David Cella
Journal:  J Gen Intern Med       Date:  2019-05-29       Impact factor: 5.128

6.  A Sequential Multiple-Assignment Randomized Trial (SMART) for Stepped Care Management of Low Back Pain in the Military Health System: A Trial Protocol.

Authors:  Julie M Fritz; Daniel I Rhon; Deydre S Teyhen; Jacob Kean; Megan E Vanneman; Eric L Garland; Ian E Lee; Richard E Thorp; Tom H Greene
Journal:  Pain Med       Date:  2020-12-12       Impact factor: 3.750

7.  End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.

Authors:  Ann T Farrell; Julie Panepinto; C Patrick Carroll; Deepika S Darbari; Ankit A Desai; Allison A King; Robert J Adams; Tabitha D Barber; Amanda M Brandow; Michael R DeBaun; Manus J Donahue; Kalpna Gupta; Jane S Hankins; Michelle Kameka; Fenella J Kirkham; Harvey Luksenburg; Shirley Miller; Patricia Ann Oneal; David C Rees; Rosanna Setse; Vivien A Sheehan; John Strouse; Cheryl L Stucky; Ellen M Werner; John C Wood; William T Zempsky
Journal:  Blood Adv       Date:  2019-12-10

Review 8.  Measurement of Chronic Pain and Opioid Use Evaluation in Community-Based Persons with Serious Illnesses.

Authors:  Kathleen Puntillo; Ramana K Naidu
Journal:  J Palliat Med       Date:  2017-11-01       Impact factor: 2.947

9.  Comparative Responsiveness of the PROMIS Pain Interference Short Forms With Legacy Pain Measures: Results From Three Randomized Clinical Trials.

Authors:  Chen X Chen; Kurt Kroenke; Timothy Stump; Jacob Kean; Erin E Krebs; Matthew J Bair; Teresa Damush; Patrick O Monahan
Journal:  J Pain       Date:  2018-12-06       Impact factor: 5.820

Review 10.  What is the current evidence of the impact on quality of life whilst waiting for management/treatment of orthopaedic/musculoskeletal complaints? A systematic scoping review.

Authors:  Joanne Morris; Asterie Twizeyemariya; Karen Grimmer
Journal:  Qual Life Res       Date:  2018-04-02       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.